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Summary: Steady-state plasma valproate (VPA) levels were analyzed in 37 
children after 6 weeks of VPA therapy. Twenty-six patients were receiving 
other antiepileptic drugs in addition to VPA (experimental group). Eleven pa- 
tients who received VPA alone served as controls. The mean VPA dose was 
not statistically different for the two groups (experimental group, 35.4 mglkgl 
day, 11.6 SD; control group, 31.1 mg/kg/day, SD 6.6) The mean plasma VPA 
level was significantly lower for the experimental group (63.0 pglml, SD 21.8) 
than for the control (99.3 pglmI), SD 23.3) (p < 0.01). VPA 1evel:dose ratio 
(LDR) was also reduced in the experimental group (1.92, SD 0.75) as compared 
to controls (3.26, SD 0.65) (p < 0.01). Within' the experimental group the VPA 
levels and VPA LDR were significantly reduced in patients receiving either 
phenytoin or phenobarbital. The data suggest that other antiepileptic drugs 
significantly alter the steady-state level to dose relationship for VPA. 
Since valproic acid (VPA) is useful as an 
adjunctive drug for controlling several sei- 
zure types (Simon and Penry, 1975; Pinder 
et al., 1977), it is frequently administered to 
patients receiving other antiepileptic drugs 
(AEDs). Interactions between VPA and 
other AEDs have been reported. VPA may 
affect the pharmacokinetics of phenytoin 
(Patsalos and Lascelles, 1977; Mattson et 
al., 1978; Bruni et al., 1979; Cramer and 
Mattson, 1979), phenobarbital (Schobben et 
al., 1975; Gram et al, 1977; Wilder et al., 
1978), and ethosuximide (Mattson and 
Cramer, 1980). Other AEDs also affect the 
kinetics of VPA. After administering a single 
oral or intravenous dose of VPA to patients 
already receiving both phenytoin and 
phenobarbital, the volume of distribution is 
larger and the elimination rate higher than 
the same parameters measured in normal 
controls (Richens et al., 1976; Perucca et 
al., 1978). Vajda et al. (1978) reported a 
flattening of the steady-state plasma level to 
dose curve with higher doses of VPA, sug- 
gesting drug interactions affecting VPA- 
levels. Bowdle et al. (1979) reported a de- 
Received December 12, 1980. 
Address correspondence and reprint requests to Dr. Sackellares at B 4906, Clinical Faculty Office Building, 
Key words: Valproic acid-Anticonvulsants-Drug interactions. 
Department of Neurology, University of Michigan Hospital, 1405 East Ann Street, Ann Arbor, Michigan 48109. 
437 
438 J .  C. SACKELLARES ET AL. 
cline in the minimum steady-state serum 
concentrations of VPA following 2 weeks of 
treatment with carbamazepine. In the pres- 
ent study, we found steady-state plasma 
VPA 1evel:dose ratios (LDR) to be lower in 
children receiving other AEDs than in chil- 
dren receiving VPA alone. 
MATERIALS AND METHODS 
VPA plasma levels were analyzed in 37 
children with absence seizures (ages 3% 
to 1811/12 years) who received VPA during a 
double-blind crossover study comparing 
VPA and ethosuximide. Twenty-six patients 
(experimental group) were receiving other 
AEDs at the time of entry into the study. In 
this group, VPA was given in addition to 
the drug or drugs taken at the time of entry. 
The control group consisted of 11 patients 
who received only VPA. The ages of the 
patients in the two groups were not signifi- 
cantly different. 
VPA was begun in doses of 10-15 mg/ 
kg/day. Doses were administered orally at 
0700, 1500, and 2300 hr daily. During the 
first 2 weeks of VPA therapy, the dose was 
increased in 5-  15 mg/kg/day increments 
until the maximum tolerated dose or 60 
mg/kg/day was reached. The doses of the 
concurrent AEDs were kept constant un- 
less side effects attributable to alterations in 
the plasma levels of these drugs occurred. 
In these cases, the dose of the responsible 
drug was adjusted to return the plasma level 
of that drug to the pre-entry level. No drug 
changes were made after 4 weeks of VPA 
therapy. Neither the physician nor the pa- 
tients knew that the active drug was VPA, 
and the physician was unaware of the VPA 
level during the course of the study. 
For purposes of the present study, drug 
levels obtained after 6 weeks of VPA ther- 
apy were analyzed. Blood samples were 
obtained at 0655 hr, prior to the 0700 hr 
dose. Drug levels were assayed by gas- 
liquid chromatography (Kupferberg, 1978). 
RESULTS 
The mean plasma VPA level and LDRs 
were significantly lower in the experimental 
group than in the control group. The mean 
VPA dosages and body weights were not 
significantly different (Table 1). Figure 1 
shows the relationship between VPA 
plasma level and VPA dose for both groups. 
This relationship was more nearly linear for 
the control group than for the experimental 
group, and the slope of the linear regression 
line was steeper (2.29) for the control group 
than for the experimental group (0.40). 
To assess the role of individual drugs af- 
fecting VPA plasma levels, the patients in 
the experimental group were further di- 
vided according to treatment. For the six 
patients who received phenobarbital and 
VPA, the LDR of VPA (1.80 r 0.68, mean 
& SD) was significantly less than those of 
patients in the control group (p < 0.01). 
There was no correlation between the 
phenobarbital level and the LDR for VPA. 
For the three patients who received phe- 
nytoin in addition to VPA, the LDR for 
VPA (1.35 2 0.34) was lower than that of 
the control group (p < 0.01). The VPA LDR 
was also significantly lower than those of 
TABLE 1. Comparison of steady-state plasma to dose relationships between 
experimental and control groups 
Variable 
Experimental Control 
( n  = 26) ( I ?  = 1 1 )  Significance 
VPA dose (mglkglday) 35.4? 11.6 31.1 t 6.6 ns 
Body weight (kg) 47.6 * 20.6 36.8 f 15.6 ns 
VPA plasma level (pglml) 63.0 f 21.8 99.3 f 23.3 p < 0.01 
LDR (pgIm1:mglkglday) 1.92 5 0.75 3.26 ? 0.65 p < 0.01 
Means ? SD are presented. Ahbreviutio/is: VPA, valproic acid; LDR, plasma 1evel:dose ratio; ns, not 
significant. 
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controls in the five patients who received 
both phenytoin and phenobarbital in addi- 
tion to VPA (2.26 k 0.72; p < 0.05). These 
values were not significantly different than 
those of patients receiving only phenytoin 
or only phenobarbital in addition to VPA. 
Only one patient received mephobarbital 
alone in addition to VPA. In this patient, 
the LDR for VPA was over two standard 
deviations lkss than that of the control 
group. For the patient who received 
primidone in addition to VPA, the LDR for 
VPA was 3.29, very close to the mean LDR 
for the control group. One patient received 
only carbamazepine in addition to VPA. 
The LDR for this patient was 2.73, less than 
one standard deviation below that of the 
mean LDR for the controls. The remaining 
12 patients in the experimental group re- 
ceived two or more drugs in addition to 
VPA. 
DISCUSSION 
The steady-state LDR of VPA was sig- 
nificantly lower in patients receiving phe- 
nytoin, phenobarbital, or both phenytoin 
and phenobarbital. The effects of phenytoin 
and phenobarbital were not additive. The 
FIG. 1. VPA dose (mg/kg/day) and 
plasma level (pg/ml) for experimental 
(0 )  and control (0) patients. The 
dotted line represents the linear re- 
gression line for the experimental 
group ( r  = 0.22, p 1 0.05). and the 
solid line represents the linear regres- 
sion line for the control group ( r  = 
0.64, p < 0.05). 
effects of the other AED steady-state VPA 
plasma levels could not be determined be- 
cause of the small number of patients in 
these groups. 
There was good correlation between the 
daily dose and plasma level when VPA was 
administered as a sole therapy (control 
group). However, there was poor correla- 
tion betweeen the daily dose and plasma 
level for subjects receiving other AEDs. 
The slope of the level to dose curve for the 
experimental group is much steeper than 
that of the control group (Fig. 1) .  This 
suggests that when VPA is used as sole 
therapy, a change in the daily maintenance 
dose will result in much larger changes in 
the steady-state plasma levels than would 
be expected in patients also receiving phe- 
nytoin or phenobarbital. 
Drug interactions of the magnitude ob- 
served in this study confound predictions of 
steady-state plasma levels. Therefore, close 
monitoring of VPA plasma levels is re- 
quired until steady state is achieved. VPA 
LDRs may also change following dosage 
changes or discontinuation of other AEDs 
and the time to reach new steady-state VPA 
levels is not known. 
Epilepsia, Vol. 22, August 1981 
440 J. C. SACKELLARES ET AL. 
The maximum tolerated doses were sim- 
ilar for subjects receiving other AEDs and 
those receiving VPA alone, even though the 
plasma levels were significantly lower in 
those receiving other drugs. This suggests 
that there was synergistic toxicity or that 
the dose-limiting side effects (drowsiness or 
nausea) were due to high free-fractions of 
VPA or phenytoin, or higher concentration 
of active metabolites of VPA as a result of 
hepatic enzyme-induction. The presence of 
phenytoin, at least in high concentrations, 
increases the plasma free-fraction of VPA 
(Cramer and Mattson, 1979; Monks et al., 
1978). The magnitude of this effect at 
steady state is not known, but probably 
varies with the concentration of both drugs. 
Since VPA is highly protein bound (Klotz 
and Antonin, 1977; Gugler and Mueller, 
1978; Cramer and Mattson, 1979), small in- 
creases in the free fraction of VPA could 
result in significant changes in both toxic 
and therapeutic effects. Therefore, the 
lower total VPA levels in patients who were 
receiving phenytoin may not accurately re- 
flect the biological activity of VPA. Mea- 
surement of the free fraction as well as total 
VPA levels may more accurately reflect the 
biological activity, particularly when VPA 
is used in combination with phenytoin. 
Since the elimination of VPA from 
plasma is of the flow-independent restric- 
tive type, only the unbound drug can be 
cleared (Klotz and Antonin, 1977). There- 
fore, an increase in the free fraction of VPA 
could have contributed to the lower 
steady-state VPA concentrations observed 
in patients receiving phenytoin. Any drug 
which competes with VPA for plasma pro- 
tein binding sites would be expected to 
have a similar effect. Phenobarbital is ap- 
proximately 40% bound to plasma protein, 
(Waddell and Butler, 1957), and there is no 
evidence that phenobarbital competes with 
VPA for plasma protein binding sites. 
Neither phenytoin or phenobarbital affects 
gastrointestinal absorption of VPA (Perucca 
et al., 1978). Therefore, it is likely that 
phenobarbital lowers steady-state VPA 
levels by induction of hepatic enzymes, as 
suggested by Gugler and Unruh (1980). If 
this be the case, the biological effects of 
VPA, for a given steady-state plasma VPA 
concentration, would depend on whether or 
not the metabolites of VPA are biologically 
active. 
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R&xJm 
Le taux plasmatique B l’kquilibre du valproate de 
sodium (VPA) a Ctk etudik chez 37 enfants aprks 6 
semaines de thkrapeutique. Vingt six patients recoivent 
d’autres rnkdicaments antiepileptiques associes au 
VPA (groupe expkrimentat) alors que 1 1  sujets 
temoins ne reGoivent que le VPA seul. La posologie 
moyenne du VPA n’est pas significativement dif- 
ferente entre les deux groupes (35,4 mg/kg/jour rt 11,6 
contre 31, l  mg/kg/jour r 6,6). Le taux plasmatique 
de VPA est significativement plus bas dam le groupe 
experimental (63,O &ml 2 21,8) contre 99,3 pglml f 
23,3 dans Ie groupe t h o i n  (p < 0,Ol). Le rapport 
taux plasmatique/posologie (LDR) a kte diminue dans 
le groupe experimental (132 2 0,75) par rapport au 
groupe temoin (3,26 f 0,65), p < 0,Ol en particulier 
chez les malades recevant de la phenytoine ou du 
PhenobarbitaI. La posologie moyenne du VPA n’ktant 
pas significativement differente dans les deux groupes, 
les faits observes suggkrent que I’addition d’autres 
antiepileptiques est capable de modifier le taux it 
YCquilibre du VPA plasmatique en fonction de la dose 
administree. 
(P. Bouyard, Marseilles) 
RESUMEN 
Se analizaron 10s niveles estables de valproato en 
plasma (VPA) en 37 nifios despuks de 6 semanas de 
terapia con VPA. Ventiseis pacientes recibian otros 
fhrmacos ademas de VPA (grupo experimental) y 
once s610 tomaban VPA y sirvieron como controles. 
La dosis media de VPA no fue significatvamente dis- 
tinta en 10s dos grupos (grupo experimental: 35,4 mg/ 
kgldia, DS 11,6; grupo control: 31.1 mg/kg/dia, DS 6,6). 
El nivel plasmAtico medio de VPA fue significativa- 
mente inferior en el grupo experimental (63,O p g h l ,  
DS 21,8) que en el control (99,3 pdml, DS 23,3), p < 
0,Ol. La relaci6n nivel de VPA: dosis (LDR) estaba 
tambikn reducida en el grupo experimental (1,92, 
DS 0,75) al compararla con 10s controles (3,26, DS 
0,65), p < 0,Ol. Dentro del grupo experimental 10s 
niveles de VPA y la LDR estaban significativamente 
reducidos en pacientes que tomaban fenitoina o fe- 
nobarbital. La dosis media no fue diferente entre 
10s grupos experimental y control. Estos datos su- 
gieren que la ingesti6n de otros fArmacos alteran 
de modo significativo 10s niveles estables de VPA en 
relaci6n con la dosis. 
(A. Portera Sanchez, Madrid) 
ZUSAMMENFASSUNG 
In steady-state befindliche Plasma Valproatspiegel 
(VPA) wurden bei 37 Kindern nach 6 wochiger VPA- 
Therapie analysiert. 26 Patienten erhielten zusht- 
zlich zum VPA andere Antiepileptika (experimentelle 
Gruppe). 1 1  Patienten, die VPA alleine bekamen, 
dienten als KontroIlen. Die mittlere VPA-Dosis war 
in beiden Gruppen nicht signifikant Vunterschiedlich 
(experimentelle Gruppe 35,4 mglkg pro Tag, 11,6 SD; 
Kontrollgruppe 31,l mg/kg pro Tag, SD 6,6). Der 
mittlere Plasma VPA-Spiegel war s ignaant  niedriger , 
in der experimentellen Gruppe (63,O pg/ml, SD 21,8) 
als in der Kontrollgruppe (99,3 pg/ml, SD 23,3), p < 
0.01. Das Verhatnis VPA-Spiegel: Dosis (LDR’ war in 
der experimentellen Gmppe ebenfalls reduziert (1,92, 
SD 0,75) gegeniiber der Kontrollgruppe (3,26, SD 0,65), 
p < 0.01. Innerhalb der experimentellen Gruppe 
waren die VPA-Spiegel und die VPNLDR bei Pa- 
tienten, die entweder Phenytoin oder Phenobarbital 
bekamen, signifikant erniedrigt. Die mittlere VPA- 
Dosis war nicht signifikant unterschiedlich in der 
experimentellen und in der Kontrollgruppe. Diese 
Daten lassen vermuten, daR andere Antiepileptika 
signifikanterweise den Steady-state-Spiegel im Hin- 
blick auf die verabfolgte Dosis VPA andern. 
(D. Scheffner, Heidelberg) 
Epilepsia, Vol. 22, August 1981 
